Ibogaine treatment Arizona comes down to two different questions: what Arizona law says about ibogaine, and what the state's 2025 research money does. In the sources we read on 31 October 2026, ibogaine is listed in federal Schedule I and in Arizona's statutory definition of a "dangerous drug", and Arizona's 2025 budget law funded a $5 million grant for an ibogaine clinical research study. The budget text sets up a grant. It does not say that ibogaine treatment is permitted. This page covers the legal text and the funding, and it says plainly what the sources do not state. It names no clinic, does not say where ibogaine is offered, and is general information, not legal advice.
Federal listing and Arizona statutes
The Drug Enforcement Administration's list of Schedule I hallucinogenic substances includes ibogaine as entry (d)(21) of 21 CFR 1308.11, with DEA code 7260 and the alternate name Tabernanthe iboga. We read that text on the eCFR through its public data service, which reported the title as up to date through 29 October 2026. No source we read shows ibogaine removed from that schedule, although we did not search the Federal Register for later DEA actions.
Arizona points to the federal list. Its statute on schedule I substances says the state board adopts by rule the schedule I substances listed in 21 CFR 1308.11 and in section 13-3401, and amends its rules to reflect changes in those designations. Section 13-3401 defines "dangerous drug" and lists "Ibogaine" among the hallucinogenic substances in that definition.
The offense statute, section 13-3407, lists acts that a person shall not knowingly do with a dangerous drug. Possessing or using one is a class 4 felony, with court options in some cases that we did not summarize. The same section makes it a class 2 felony to administer a dangerous drug to another person, and also a class 2 felony to possess one for sale, to manufacture one, or to transport one for sale, import it or sell or transfer it. We did not read sentencing ranges or case law.
A separate statute, section 13-3412, says that section 13-3407 and several other sections do not apply to certain people. Among them are medical practitioners, pharmacies and pharmacists acting in the course of their professional practice, in good faith and in accordance with generally accepted medical standards, and persons who lawfully acquire and use such drugs only for scientific purposes. Subsection C puts the burden of proving an exception on the defendant. This page does not say whether either exception covers any ibogaine activity, including the funded study described below, and we read no court decision or agency guidance on that question.
That is a description of statute text, not a prediction about any case. Whether a particular act is an offense depends on facts and on law we did not review, and a person with that question needs an Arizona lawyer.
What Arizona funded in 2025
The research money is in the state's 2025 budget law, Laws 2025, Chapter 233 (Senate Bill 1735), which closes with the line "Approved by the governor June 27, 2025." In the Department of Health Services appropriation, section 43 lists a line item called "Ibogaine clinical research grants" at $5,000,000 for fiscal year 2025-26, marked with an asterisk. It directs the department to use the money to award a grant for a certified clinical research study on using ibogaine to treat neurological diseases.
The department may award the grant only to an entity that meets three tests: a history of proven research and treatment of neurological diseases, a neurosurgery program with the requisite clinical and research facilities, and the ability to facilitate pioneering research and innovation in diagnosing and treating neurological conditions.
Conditions attached to the money
The asterisk is explained in section 144 of the chapter, not in a footnote: it means the appropriation is a continuing appropriation exempt from the state law on lapsing of appropriations (section 35-190). We did not read how the department treated that in practice.
We searched the full text of the chapter. The word "ibogaine" appears only in section 43, and the chapter contains no matching-funds condition for this grant. An earlier standalone bill did: the House-engrossed text of House Bill 2871 would have appropriated the same $5,000,000 and added a fourth eligibility test, a demonstrated commitment of at least $5,000,000 in matching gifts, grants and donations from sources other than the state. We found no record that HB 2871 was enacted, but the Legislature's own bill-status page would not load for us, so we state only what the two texts say.
Where the funded study stands
On 5 August 2026 the Barrow Neurological Institute, in a news article on its own site, said it had received a $5 million grant from the Arizona Department of Health Services to study ibogaine in people with neurological disorders such as traumatic brain injury. It describes a phase 1/2 trial that aims to enroll 40 people with chronic symptoms of traumatic brain injury, assigned at random to ibogaine or placebo, and says researchers hope to enroll the first participant in 2027.
This is the grantee's own statement. We did not find the department's announcement of the award, a trial registration or a federal investigational new drug record, so we cannot say where the trial is in its regulatory steps. Nothing we read describes open enrollment or how a person would take part in the study.
What the funding does and does not mean
Section 43 is an appropriation. Only sections 1 to 3 of Chapter 233 amend the 2024 budget act; sections 4 to 146, including section 43, are the 2025-26 appropriations act itself. Ibogaine appears in the chapter only in section 43, the chapter never refers to A.R.S. 13-3401, 13-3407, 13-3412 or 36-2512, and none of its text says that ibogaine possession, supply or treatment outside a study is permitted.
The research money and the criminal statutes sit side by side. Funding a trial says that the state wants evidence on a question. It does not change the Schedule I listing or tell us anything about an individual clinic.
Legal status is not a safety signal
A substance's legal position and its medical risk are separate questions. A 2026 review in the journal Addiction describes a rare but clinically significant risk of prolonged QTc interval and potentially fatal ventricular arrhythmias with ibogaine, reports published cardiac events at therapeutic doses including in people with no known heart disease, and calls for treatment only under controlled medical supervision with close monitoring of heart function. We read the abstract only. It does not say that any setting is safe, and neither does this page.
What we could not confirm
- The Arizona Department of Health Services' own pages on the grant, including how it solicited applications and what it awarded. The addresses we tried on 30 October returned "not found" errors, and we did not rely on third-party reposts.
- Whether any 2026 Arizona bill, rule or board action touches ibogaine. We found none in the sources we read, but we did not search the 2026 session records in full.
- The final action recorded on House Bill 2871 by the Legislature itself, and any terms the department put in the grant agreement, including any matching requirement it may have asked of the grantee.
- Anything a lawyer would add. No lawyer or agency was contacted.
How this page was made
We read each source named here on 31 October 2026, except that the Department of Health Services pages were tried on 30 October. The federal regulation came from the eCFR. Arizona statutes, the budget chapter and the text of House Bill 2871 came from the Arizona Legislature's website, and we searched the chapter's full text rather than reading every line. We did not use clinic or provider pages as sources, and we did not contact anyone. Laws and agency actions change, so check current sources before relying on this page. If you or someone you know has a health question about ibogaine or about stopping a substance, talk with a qualified physician.
Evidence and Scope
Sources and Limits
These sources explain general treatment settings and questions. Check the services, professionals and arrangements of each program directly.
- Electronic Code of Federal Regulations, 21 CFR 1308.11 (DEA Schedule I)Text read on 2026-10-31 on the eCFR itself through its public versioner data service (title 21 reported up to date as of 2026-10-29); the website pages redirect automated readers to an unblock page, so the data service was used. Paragraph (d) lead-in and entry (d)(21) were read. Says nothing about Mexican law or about any clinic; the Federal Register was not searched for later DEA actions.Observed
- Arizona Legislature, A.R.S. 36-2512 (Substances in schedule I; rules)Statute text read on 2026-10-31 through an automated summarizing fetch of the Arizona Legislature page, so paraphrases need a human check against the full text. Subsection A was read; the fetch quoted only the opening words and summarized the rest; the page showed no amendment note. Describes how the state schedule is adopted, not how any act is charged.Observed
- Arizona Legislature, A.R.S. 13-3401 (Definitions; dangerous drug)Statute text read on 2026-10-31 through an automated summarizing fetch of the Arizona Legislature page, so paraphrases need a human check against the full text. Only the 'dangerous drug' lead-in and the hallucinogen item (paragraph 6(a)(xviii)) were checked; the page showed no amendment note and did not mention Tabernanthe iboga.Observed
- Arizona Legislature, A.R.S. 13-3407 (Possession, use, administration, acquisition, sale, manufacture or transportation of dangerous drugs)Statute text read on 2026-10-31 through an automated summarizing fetch of the Arizona Legislature page, so paraphrases need a human check against the full text. Subsection A (paragraphs 1 to 7) and the felony classes in subsection B were read; the conditions in B(1) for a misdemeanor or probation, sentencing ranges, other subsections and case law were not summarized. Not a statement about any particular act.Observed
- Arizona Legislature, A.R.S. 13-3412 (Exceptions to chapter provisions)Statute text read on 2026-10-31 through an automated summarizing fetch of the Arizona Legislature page, so paraphrases need a human check against the full text. Subsection A and the burden-of-proof wording of subsection C were read; subsection A also lists other exceptions (for example paragraph 8 on seriously or terminally ill patients with a doctor's prescription under section 13-3412.01), which were not summarized. The page showed no amendment note. It says nothing about ibogaine, and no court decision or agency guidance on the exceptions was read.Observed
- Arizona Legislature, Laws 2025, Chapter 233 (Senate Bill 1735, general appropriations)The chapter page (about 307,000 characters of text) was downloaded and searched on 2026-10-31 for 'ibogaine', 'match', 'continuing appropriation', 'dangerous drug', 'schedule I', 'Tabernanthe', '13-34' and '36-2512'; section 43, section 144 and the closing approval line were read in context. It was searched rather than read line by line, and the effective-date provisions were not read. An appropriation is not a statement about whether treatment is permitted.Observed
- Arizona Legislature, House Bill 2871 (2025, First Regular Session), House Engrossed textBill text read on 2026-10-31 through an automated summarizing fetch. A bill is not law. The Legislature's own bill-status page could not be read (the request looped through redirects), so the bill's final action is not established from an official source; a third-party tracker (BillTrack50, discovery only and not relied on) lists it as dead on 2025-06-27 after a Senate Appropriations committee 'do pass' vote on 2025-03-11.Observed
- Barrow Neurological Institute, news article dated 2026-08-05The grantee's own news statement, read on 2026-10-31; not independent, and it does not cite a trial registration or federal investigational new drug record. The Department of Health Services' own announcement was not found.Observed
- Addiction 2026;121(6):1616-1621, Brunt TM, PubMed record PMID 41560340, DOI 10.1111/add.70319Narrative review abstract read on 2026-10-31 on PubMed. Describes cardiac risk and supervision recommendations; it gives no legal analysis, no clinic assessment and no individual medical advice. No qualified clinical review of this article is recorded.Observed